It certainly is. Another question is whether a three drug GS-7977/Riba/? will be the first oral on the market. A lot depends on the results in GT1 treatment-naive patients. Another issue is are we looking at viral relapse or viral mutation in nulls and potentially naive patients?
Market Data 
Markets 
AI
